Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-CHUK Antibody (R2U34)

Catalog #:   RHA41603 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG1
Applications: FCM, IF, WB
Accession: O15111
Overview

Catalog No.

RHA41603

Species reactivity

Human

Host species

Mouse

Isotype

IgG1

Clonality

Monoclonal

Applications

FCM, IF, WB

Recommended Dilution

Application Dilution
FCM 1:200-1:400, IF: 1:200-1:1000, WB: 1:500-1:2000

Target

IKK-A, I-kappa-B kinase alpha, Transcription factor 16, TCF-16, CHUK, NFKBIKA, Inhibitor of nuclear factor kappa-B kinase subunit alpha, IKKA, TCF16, Nuclear factor NF-kappa-B inhibitor kinase alpha, I-kappa-B kinase 1, Conserved helix-loop-helix ubiquitous kinase, IKK1, IkappaB kinase, IKK-alpha, IkBKA

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

O15111

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R2U34

Note

For research use only.

Data Image
  • Flow Cytometry
    Flow cytometric analysis of A549 cells using CHUK mouse mAb (blue) and negative control (red).
  • Immunofluorescence
    Immunofluorescence analysis of NIH/3T3 cells using CHUK mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.
  • Western blot
    Western blot analysis using CHUK mouse mAb against Raji (1), Jurkat (2), THP-1 (3) and K562 (4) cell lysate.
References

The presentation and natural history of immunodeficiency caused by nuclear factor kappaB essential modulator mutation., PMID:15100680

Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K/Akt pathway and of IkappaB kinase activity., PMID:15113757

Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation., PMID:15247285

Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling., PMID:15252836

Proteome analysis of lipid rafts in Jurkat cells characterizes a raft subset that is involved in NF-kappaB activation., PMID:15253425

Gamma-interferon enhances expression of CD14/MyD88 and subsequent responsiveness to lipopolysaccharide from Actinobacillus actinomycetemcomitans in human gingival fibroblasts., PMID:15324355

Molecular analysis of a large cohort of patients with the hyper immunoglobulin M (IgM) syndrome., PMID:15358621

Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration., PMID:15385607

Identification of hypoxia-regulated proteins in head and neck cancer by proteomic and tissue array profiling., PMID:15492250

Negative regulation of JNK signaling by the tumor suppressor CYLD., PMID:15496400

The molecular adapter Carma1 controls entry of IkappaB kinase into the central immune synapse., PMID:15520247

Stress-induced inhibition of the NF-kappaB signaling pathway results from the insolubilization of the IkappaB kinase complex following its dissociation from heat shock protein 90., PMID:15611262

Peripheral lipopolysaccharide induces apoptosis in the murine olfactory bulb., PMID:15781053

Inhibition of IKK down-regulates antigen + IgE-induced TNF production by mast cells: a role for the IKK-IkappaB-NF-kappaB pathway in IgE-dependent mast cell activation., PMID:15784689

NEMO mutations in 2 unrelated boys with severe infections and conical teeth., PMID:15833888

B cell receptor (BCR) cross-talk: CD40 engagement creates an alternate pathway for BCR signaling that activates I kappa B kinase/I kappa B alpha/NF-kappa B without the need for PI3K and phospholipase C gamma., PMID:15879100

alpha3beta1 integrin induced suppression of the Caco-2 epithelial cell IL-1 signaling pathway leading to NF-(kappa)B activation., PMID:15919367

Inverse regulation of the nuclear factor-kappaB binding to the p53 and interleukin-8 kappaB response elements in lesional psoriatic skin., PMID:15955105

B-1 cells are deficient in Lck: defective B cell receptor signal transduction in B-1 cells occurs in the absence of elevated Lck expression., PMID:15972627

Alpha-lipoic acid inhibits TNF-alpha induced NF-kappa B activation through blocking of MEKK1-MKK4-IKK signaling cascades., PMID:18182252

Lung transplantation in Hong Kong: 12 years of experience., PMID:18811889

ATM mediates constitutive NF-kappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia., PMID:19079347

Activation of endothelial intrinsic NF-{kappa}B pathway impairs protein C anticoagulation mechanism and promotes coagulation in endotoxemic mice., PMID:19620400

Resistin up-regulates COX-2 expression via TAK1-IKK-NF-kappaB signaling pathway., PMID:19774455

Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways., PMID:20448286

Mechanisms of the apoptosis induced by CD176 antibody in human leukemic cells., PMID:21455576

Lipopolysaccharide enhances decorin expression through the Toll-like receptor 4, myeloid differentiating factor 88, nuclear factor-kappa B, and mitogen-activated protein kinase pathways in odontoblast cells., PMID:22414830

Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697., PMID:23338544

Lack of association of variants previously associated with anti-TNF medication response in rheumatoid arthritis patients: results from a homogeneous Greek population., PMID:24040234

Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis., PMID:25896535

Conditional Deletion of NF-κB-Inducing Kinase (NIK) in Adult Mice Disrupts Mature B Cell Survival and Activation., PMID:26116508

Palliative care for a patient with Lambert-Eaton myasthenic syndrome: role of 3,4-diaminopyridine., PMID:27506750

Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis., PMID:27977334

U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab., PMID:28087644

FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma., PMID:28235882

Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis., PMID:29361469

Novel heterozygous pathogenic variants in CHUK in a patient with AEC-like phenotype, immune deficiencies and 1q21.1 microdeletion syndrome: a case report., PMID:29523099

GNAI1 and GNAI3 Reduce Colitis-Associated Tumorigenesis in Mice by Blocking IL6 Signaling and Down-regulating Expression of GNAI2., PMID:30836096

Serological diagnosis of Mycobacterium avium complex lung diseases by enzyme immunoassay of IgA antibodies against MAC-specific glycopeptidolipid core antigen., PMID:32995571

Autophagic feedback-mediated degradation of IKKα requires CHK1- and p300/CBP-dependent acetylation of p53., PMID:33097607

Anti-tumour necrosis factor-alpha response associated with combined CD226 and HLA-DRB1[*]0404 haplotype in rheumatoid arthritis., PMID:33427622

FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib., PMID:33973307

Humanized anti‑TLR4 monoclonal antibody ameliorates lipopolysaccharide‑related acute kidney injury by inhibiting TLR4/NF‑κB signaling., PMID:34184086

Therapeutic effects of quinine in a mouse model of atopic dermatitis., PMID:34240224

FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC., PMID:35101885

Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials., PMID:35219582

NF-ΚB Activation as a Key Driver in Chronic Lymphocytic Leukemia Evolution to Richter's Syndrome: Unraveling the Influence of Immune Microenvironment Dynamics., PMID:39596634

Assessment of Unexpected (Non-ABO) Red Blood Cell Antibodies and Their Associated Clinical Conditions Among Patients and Blood Donors Attending University Teaching Hospital of Kigali (CHUK) and Rwanda Blood Transfusion Division., PMID:40151361

Emerging Strategies and Progress in the Medical Management of Marburg Virus Disease., PMID:40333077

Marburg virus disease in Rwanda: an observational study of the first 10 days of outbreak response, clinical interventions, and outcomes., PMID:40394565

Datasheet

Document Download

Anti-CHUK Antibody (R2U34).pdf

 

$ 220
Product specifications
50 μg 220 100 μg 350

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-CHUK Antibody (R2U34) [RHA41603]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only